Should you buy Pacira BioSciences (PCRX)?
Updated
Pacira BioSciences trades below the $1 billion minimum investable universe threshold at $890 million market cap, carries a perfect 9/9 Piotroski F-Score with exceptional free cash flow conversion, but faces 24% short interest, a put/call ratio of 7.00, and capitulation-risk RSI near 30 — making this a sub-threshold speculative situation rather than a standard investment.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Pacira BioSciences has a market cap of $890 million, which is below the $1 billion minimum size threshold for the investable universe — this cap constraint removes it from standard portfolio consideration regardless of other fundamental factors. Warnings | Market cap recovers above $1 billion within 12 months as price rises above $25.81 analyst target, returning the stock to investable universe eligibility. | →Stable |
| CounterWith 24% short interest and a put/call ratio of 7.00, the market is positioned for continued price weakness that could push market cap further below the $1 billion threshold rather than recovering above it. | ||
Despite sub-threshold market cap, Pacira earns a perfect 9/9 Piotroski F-Score and converts 1,000% of net income into free cash flow — the highest cash conversion in the dataset — indicating exceptional balance sheet quality relative to its small size. Quality breakdown | Free cash flow conversion stays above 500% of net income for at least 3 of the next 4 quarters, sustaining the Piotroski quality signal. | →Stable |
| CounterA 1,000% free cash flow to net income ratio is extremely unusual and may reflect accounting or timing anomalies rather than durable cash generation; the Rule of 40 score of only 18 indicates the business is not delivering combined growth and margin performance at a competitive level. | ||
With 24% short interest and a put/call ratio of 7.00 — the highest in the dataset — bearish positioning is at an extreme level that creates significant short-covering risk if any positive catalyst emerges. Options | Short interest falls below 15% within 12 months as the bearish thesis is tested by upcoming earnings results. | →Stable |
| CounterA 7.00 put/call ratio is extraordinarily bearish and typically reflects informed options positioning around a specific known risk — such as clinical trial data, regulatory review, or competitive threat — that is not visible in the quantitative data. | ||
Pacira BioSciences has a market cap of $890 million, which is below the $1 billion minimum size threshold for the investable universe — this cap constraint removes it from standard portfolio consideration regardless of other fundamental factors.
→Stable- Expectation
- Market cap recovers above $1 billion within 12 months as price rises above $25.81 analyst target, returning the stock to investable universe eligibility.
CounterWith 24% short interest and a put/call ratio of 7.00, the market is positioned for continued price weakness that could push market cap further below the $1 billion threshold rather than recovering above it.
Despite sub-threshold market cap, Pacira earns a perfect 9/9 Piotroski F-Score and converts 1,000% of net income into free cash flow — the highest cash conversion in the dataset — indicating exceptional balance sheet quality relative to its small size.
→Stable- Expectation
- Free cash flow conversion stays above 500% of net income for at least 3 of the next 4 quarters, sustaining the Piotroski quality signal.
CounterA 1,000% free cash flow to net income ratio is extremely unusual and may reflect accounting or timing anomalies rather than durable cash generation; the Rule of 40 score of only 18 indicates the business is not delivering combined growth and margin performance at a competitive level.
With 24% short interest and a put/call ratio of 7.00 — the highest in the dataset — bearish positioning is at an extreme level that creates significant short-covering risk if any positive catalyst emerges.
→Stable- Expectation
- Short interest falls below 15% within 12 months as the bearish thesis is tested by upcoming earnings results.
CounterA 7.00 put/call ratio is extraordinarily bearish and typically reflects informed options positioning around a specific known risk — such as clinical trial data, regulatory review, or competitive threat — that is not visible in the quantitative data.
▸ Show 1 more pillar▾ Show fewer
Pacira has beaten earnings in 3 of the last 4 quarters, and with RSI near 30 at capitulation-risk levels, the combination of positive earnings delivery and oversold technical conditions creates a setup where the next beat could catalyze a meaningful price recovery.
→Stable- Expectation
- Earnings beat consensus by more than 5% in the next quarter and price rises above $25 within 30 days of the report.
CounterThe most recent miss was a severe 37% shortfall that overwhelmed the prior beat streak; capitulation-risk RSI in a name with extreme bearish options positioning may reflect genuine fundamental deterioration rather than technical oversold conditions.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pacira BioSciences has a market cap of $890 million, which is below the $1 billion minimum size threshold for the investable universe — this cap constraint removes it from standard portfolio consideration regardless of other fundamental factors.
Trip ifMarket cap falls below $750 million for more than 20 consecutive trading days, moving further below the minimum investable threshold.
- P2Despite sub-threshold market cap, Pacira earns a perfect 9/9 Piotroski F-Score and converts 1,000% of net income into free cash flow — the highest cash conversion in the dataset — indicating exceptional balance sheet quality relative to its small size.
Trip ifFree cash flow conversion falls below 200% of net income for 2 consecutive quarters, indicating the quality signal has deteriorated.
- P3With 24% short interest and a put/call ratio of 7.00 — the highest in the dataset — bearish positioning is at an extreme level that creates significant short-covering risk if any positive catalyst emerges.
Trip ifShort interest rises above 30% of float, indicating bearish conviction is intensifying beyond already-elevated levels.
- P4Pacira has beaten earnings in 3 of the last 4 quarters, and with RSI near 30 at capitulation-risk levels, the combination of positive earnings delivery and oversold technical conditions creates a setup where the next beat could catalyze a meaningful price recovery.
Trip ifEarnings miss consensus by more than 20% in the upcoming quarter and price drops below $19 within 5 trading days of the report.
How the engine reached this verdict
TrendMatrix's engine output for Pacira BioSciences, Inc. (PCRX) is HOLD_IF_HOLDING with medium conviction, score 5.0/10 at $23.98. An L1 hard-floor gate blocked the positive-verdict path — Market cap $0.94B below $1B minimum. Not in investable universe. Co-failing gates ( ASYMMETRY:1.0<1.5@spot) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
HOLD flips toward BUY_WAIT if reward-to-risk at 1.0 vs threshold 1.5 clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $22.35 for existing positions. Asymmetric R:R is 1.27, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Market cap $0.94B below $1B minimum. Active engine warnings: Market cap $0.94B below $1B minimum, V9 Gate Failed: ASYMMETRY:1.0<1.5@spot.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PCRX — 10-dimension breakdown →
Bear case
- ▸Market cap $0.94B below $1B minimum